Literature DB >> 15724085

Communication between the perilymphatic scalae and spiral ligament visualized by in vivo MRI.

Jing Zou1, Ilmari Pyykkö, Börje Bjelke, Prasun Dastidar, Esko Toppila.   

Abstract

We evaluated the transport of Gadolinium-diethylenetriaminepentaacetate-bismethylamide (Gd-DTPA-BMA) through the round window (RW) membrane into the perilymphatic space with 4.7-T MRI in an animal study and 1.5-T MRI in humans. After administration of Gd-DTPA-BMA onto the intact RW membrane of guinea pig, Gd-DTPA-BMA uptake was observed in the basal turn and part of the second turn within 40 min. The scala tympani, scala vestibuli, the fibrous part of the spiral ligament and semicircular canal all showed uptake of Gd-DTPA-BMA. All turns of the cochlea were filled with Gd within 10 min in the perforated RW membrane administration group and within 30 min in the intravenous administration group. In patients who accepted middle ear injection of Gd-DTPA-BMA, uptake was observed within 2 h in the basal turn and semicircular canal. After 12 h the apex did still not show any uptake. Gd-DTPA-BMA is transported from the RW to the semicircular canal, the scala tympani and scala vestibuli without passing the helicotrema. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724085     DOI: 10.1159/000084024

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  31 in total

1.  Murine intracochlear drug delivery: reducing concentration gradients within the cochlea.

Authors:  David A Borkholder; Xiaoxia Zhu; Brad T Hyatt; Alfredo S Archilla; William J Livingston; Robert D Frisina
Journal:  Hear Res       Date:  2010-05-06       Impact factor: 3.208

2.  Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model.

Authors:  Stefan K Plontke; Norbert Siedow; Raimund Wegener; Hans-Peter Zenner; Alec N Salt
Journal:  Audiol Neurootol       Date:  2006-11-17       Impact factor: 1.854

3.  Imaging of endolymphatic and perilymphatic fluid at 3T after intratympanic administration of gadolinium-diethylene-triamine pentaacetic acid.

Authors:  S Naganawa; M Sugiura; M Kawamura; H Fukatsu; M Sone; T Nakashima
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-09       Impact factor: 3.825

4.  Does intratympanic gadolinium injection predict efficacy of gentamicin partial chemolabyrinthectomy in Menière's disease patients?

Authors:  Gerd Claes; Luc Van den Hauwe; Floris Wuyts; Paul Van de Heyning
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-28       Impact factor: 2.503

5.  MR volumetric assessment of endolymphatic hydrops.

Authors:  R Gürkov; A Berman; O Dietrich; W Flatz; C Jerin; E Krause; D Keeser; B Ertl-Wagner
Journal:  Eur Radiol       Date:  2014-10-16       Impact factor: 5.315

6.  Intratympanic Contrast in the Evaluation of Menière Disease: Understanding the Limits.

Authors:  J Bykowski; J P Harris; M Miller; J Du; M F Mafee
Journal:  AJNR Am J Neuroradiol       Date:  2015-03-26       Impact factor: 3.825

7.  [On the diagnosis of Menière's disease : Discussion of the new criteria].

Authors:  R Gürkov
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

8.  Enhanced oval window and blocked round window passages for middle-inner ear transportation of gadolinium in guinea pigs with a perforated round window membrane.

Authors:  Jing Zou; Ilmari Pyykkö
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-12-11       Impact factor: 2.503

9.  Clinical features of delayed endolymphatic hydrops and intralabyrinthine schwannoma : An imaging-confirmed comparative case series. English version.

Authors:  C Jerin; E Krause; B Ertl-Wagner; R Gürkov
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

10.  [Clinical features of delayed endolymphatic hydrops and intralabyrinthine schwannoma : An imaging-confirmed comparative case series. German version].

Authors:  C Jerin; E Krause; B Ertl-Wagner; R Gürkov
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.